Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Inclusion Criteria

• •Participants must sign an approved informed consent form (ICF)
• •Histologically or cytologically confirmed epithelial ovarian/fallopian tube/primary peritoneal carcinoma
• •Patients had to have received a front-line, platinum/taxane based chemotherapy regimen
• •Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer or progressed within six months of completing the most recent platinum-based chemotherapy
• •Participants must have received prior platinum-based chemotherapy for management of primary disease but must not have received more than 3 prior systemic cytotoxic regimens.
• •Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area and increased Ca 125
• •A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment
• •Age 20-75 years old
• •Performance status (WHO) 0-2
• •Life expectancy of at least three months
• •Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)
• •Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl)